From the Editor-in-Chief: Many of the Toughest Biologicals are Becoming Easier to Produce
BioProcessing Journal · 28.07.2026 · 3
DOI: 10.12665/j154.carson ↗Kurz gefasst
Fachartikel in der Zeitschrift BioProcessing Journal, online erschienen am 28.07.2026. Verfasst von Keith L. Carson.
Abstract (Originalsprache)
There are so many exciting things happening in the biotech industry. As we have all seen, antibody products are being approved for more and more cancer applications, in addition to those for auto-immune diseases, which used to dominate how they were being used. And of course, these applications are in addition to the many which use antibodies conjugated to chemotherapeutic drugs and imaging agents—where the antibody acts as a targeting mechanism. Then there are the hundreds of monoclonal and polyclonal antibody applications that have dominated diagnostic testing for decades...
Zitieren
APA
Carson, K. L. (2026). From the Editor-in-Chief: Many of the Toughest Biologicals are Becoming Easier to Produce. BioProcessing Journal, 3. https://doi.org/10.12665/j154.carson
Vancouver
Carson KL. From the Editor-in-Chief: Many of the Toughest Biologicals are Becoming Easier to Produce. BioProcessing Journal. 2026:3. doi:10.12665/j154.carson
BibTeX
@article{Carson2026,
author = {Carson, Keith L.},
title = {From the Editor-in-Chief: Many of the Toughest Biologicals are Becoming Easier to Produce},
journal = {BioProcessing Journal},
year = {2026},
pages = {3},
doi = {10.12665/j154.carson}
}
EUVIMED